Nipocalimab for Healthy Subjects

This trial examines how a medication called nipocalimab appears in breast milk after administering a single dose to healthy, breastfeeding women. Researchers aim to understand how nipocalimab moves and changes in the body. The trial seeks women who have been breastfeeding for a while and are exclusively nursing their babies. Participants should not have a history of breast surgery or any current breast infections. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new medication.

Research has shown that nipocalimab is generally safe for people. In studies involving patients with generalized myasthenia gravis, the number of serious side effects was similar to those taking a placebo (a harmless pill with no active medicine). Specifically, 9% of patients taking nipocalimab experienced serious side effects, compared to 14% in the placebo group. This suggests that nipocalimab is relatively safe, with side effects comparable to not taking the treatment. Some patients reported common side effects, such as infections, but these were not specific to nipocalimab. Overall, current evidence supports the safety of nipocalimab in people.¹²³⁴⁵

Unlike the standard treatments for autoimmune conditions, which often include broad immunosuppressants, nipocalimab works differently by specifically targeting the neonatal Fc receptor (FcRn). This precise mechanism helps reduce the levels of pathogenic antibodies without broadly suppressing the immune system, potentially leading to fewer side effects. Researchers are excited about nipocalimab because it promises a more targeted approach that might improve safety and effectiveness compared to existing options.

Research has shown that nipocalimab is generally safe and well-tolerated at various doses. In studies, participants safely received doses up to 60 mg/kg. Nipocalimab interacts with a protein that regulates the immune system, making it a candidate for study in various conditions. In this trial, healthy lactating participants will receive a single dose of nipocalimab to assess its presence in breast milk. Although research remains in the early stages, these findings suggest that nipocalimab could become a safe and effective treatment in the future.⁶⁷⁸⁹¹⁰